Keywords: coulter, completes, patient, enrollment, bexxar, trial, pharmaceutical

Coulter Completes Patient Enrollment In Bexxar Trial

Article | 26 March 1998

Print This

Coulter Pharmaceutical has reached its target patient enrollment of61 in a Phase III trial of Bexxar (anti-CD20 monoclonal antibody labeled ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in